UNSPSC 51263602: Doxazosin

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C23H25N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NW1291F1W8, chemically known as 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin but generally known as doxazosin, which bears US NIH Compound Identifier 3157. European Medicines Agency schedules Doxazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06384MIG.

UNSPSC 51263602 Doxazosin, a Commodity code, nominally describes a specific antihypertensive pharmaceutical, but the recent state and local procurement activity tagged to this code does not align with that scope. Seminole County, Florida issued IFB 60459723LAS seeking to procure naloxone and safe drug deactivation systems—emergency response and harm-reduction supplies unrelated to doxazosin therapy. The mismatch suggests either a coding error in the county's tagging or a broader categorization issue within the jurisdiction's procurement system. Based on the single recent opportunity available, the code shows no clearly relevant state and local contract activity for doxazosin itself or pharmaceuticals within its therapeutic class.

Seminole County's naloxone and drug deactivation procurement, posted June 30, 2026 with a response deadline of July 26, 2023, represents an outlier tagged to this code. The county sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The IFB required electronic submission, unit pricing for each line item, E-Verify compliance, and drug-free workplace certification, with a two-year initial term and one-year renewal option. Potential FEMA funding introduced additional federal compliance requirements. Without additional recent opportunities under this code from other state or local issuing bodies, the activity available for analysis is insufficient to characterize issuing-body patterns, geographic concentration, or procurement trends relevant to doxazosin or related pharmaceutical commodities.